NO922029L - Fremgangsmaate for fremstilling og anvendelse av en herpes-protease - Google Patents

Fremgangsmaate for fremstilling og anvendelse av en herpes-protease

Info

Publication number
NO922029L
NO922029L NO92922029A NO922029A NO922029L NO 922029 L NO922029 L NO 922029L NO 92922029 A NO92922029 A NO 92922029A NO 922029 A NO922029 A NO 922029A NO 922029 L NO922029 L NO 922029L
Authority
NO
Norway
Prior art keywords
protease
herpes
protein
methods
viral
Prior art date
Application number
NO92922029A
Other languages
English (en)
Other versions
NO922029D0 (no
NO303645B1 (no
Inventor
Bernard Roizman
Fenyong Liu
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/832,855 external-priority patent/US5478727A/en
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Publication of NO922029D0 publication Critical patent/NO922029D0/no
Publication of NO922029L publication Critical patent/NO922029L/no
Publication of NO303645B1 publication Critical patent/NO303645B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO922029A 1991-05-24 1992-05-22 Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor NO303645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70581491A 1991-05-24 1991-05-24
US07/832,855 US5478727A (en) 1991-05-24 1992-02-07 Methods and compositions for the preparation and use of a herpes protease

Publications (3)

Publication Number Publication Date
NO922029D0 NO922029D0 (no) 1992-05-22
NO922029L true NO922029L (no) 1992-11-25
NO303645B1 NO303645B1 (no) 1998-08-10

Family

ID=27107575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922029A NO303645B1 (no) 1991-05-24 1992-05-22 Testmetode for Õ identifisere en forbindelse som er i stand til Õ inhibere en herpes simplex (HSV) protease og anvendelse av et proteinsubstrat og anvendelse av inhibitor

Country Status (13)

Country Link
EP (1) EP0514830B1 (no)
JP (1) JP3355202B2 (no)
AT (1) ATE192494T1 (no)
AU (1) AU666305B2 (no)
CA (1) CA2069460C (no)
DE (2) DE69230984T4 (no)
ES (1) ES2145742T3 (no)
FI (1) FI104427B (no)
HU (1) HU216622B (no)
IE (1) IE921656A1 (no)
IL (1) IL101975A (no)
NO (1) NO303645B1 (no)
NZ (1) NZ242739A (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406902B1 (en) 1991-07-05 2002-06-18 Johns Hopkins University Herpes virus proteinase and methods of assaying
US5434074A (en) * 1991-07-05 1995-07-18 Gibson; D. Wade Cytomegalovirus proteinase
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
EP0708833A1 (en) * 1993-06-08 1996-05-01 Abbott Laboratories Herpes simplex virus type-2 protease
CA2169748A1 (en) * 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
US5506115A (en) * 1994-04-29 1996-04-09 G. D. Searle & Co. Reagent and method for determining activity of herpes protease
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US5486470A (en) * 1994-07-21 1996-01-23 Merck & Co., Inc. Purified herpes simplex virus protease and methods of purification
US5618685A (en) * 1995-04-06 1997-04-08 Merck & Co., Inc. Activation of herpes simplex virus protease by kosmotropes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
WO1996038546A1 (en) * 1995-06-01 1996-12-05 Merck & Co., Inc. Herpes simplex type 1 protease mutants and vectors
US6083711A (en) * 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
IL142636A0 (en) * 1998-10-30 2002-03-10 Cellomics Inc A system for cell-based screening
WO2001046448A1 (en) 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3800233A1 (de) * 1988-01-07 1989-07-20 Hans Prof Dr Dr Wolf Methoden fuer die gentechnologische produktion einer rekombinanten, enzymatisch aktiven hiv spezifischen protease und der vorlaeufermolekuele der gruppenspezifischen antigene (gag) und der polymerase (pol) und verwendung dieser produkte in ansaetzen zur testung von hiv-protease spezifischen inhibitoren

Also Published As

Publication number Publication date
EP0514830A2 (en) 1992-11-25
DE69230984T2 (de) 2000-11-02
ATE192494T1 (de) 2000-05-15
CA2069460A1 (en) 1992-11-25
NO922029D0 (no) 1992-05-22
HU216622B (hu) 1999-07-28
NO303645B1 (no) 1998-08-10
HUT65494A (en) 1994-06-28
FI104427B (fi) 2000-01-31
DE69230984T4 (de) 2001-04-05
CA2069460C (en) 2002-12-31
FI922271A0 (fi) 1992-05-19
JP3355202B2 (ja) 2002-12-09
HU9201723D0 (en) 1992-08-28
IL101975A (en) 1998-08-16
ES2145742T3 (es) 2000-07-16
DE69230984D1 (de) 2000-06-08
IE921656A1 (en) 1992-12-02
NZ242739A (en) 1994-12-22
FI922271A (fi) 1992-11-25
AU1711292A (en) 1992-11-26
JPH05336964A (ja) 1993-12-21
EP0514830B1 (en) 2000-05-03
AU666305B2 (en) 1996-02-08
EP0514830A3 (en) 1993-06-09

Similar Documents

Publication Publication Date Title
NO922029D0 (no) Fremgangsmaate for fremstilling og anvendelse av en herpes-protease
DK217288D0 (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DK0784483T3 (da) Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
ATE451462T1 (de) Klonierung und expression von htlv-iii-dns
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
EP0269455A3 (en) Highly purified fused protein comprising human ige fc fragment and production thereof
EP0252588A3 (en) Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
Roizman et al. Methods and compositions for the preparation and use of a herpes protease
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE69232122T2 (de) Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle.
RU94030478A (ru) Рекомбинантный вирус, способ его получения, способ иммунизации, способ получения протеина, вакцинная композиция, применение рекомбинантного вируса
TH63069A (th) โคลนก่อการติดเชื้อ
BR9710830A (pt) Processo para produção de fator de crescimento do vìrus bean58058 (begf) recombinante e da proteìna do begf recombinante.
FI98466B (fi) FSME-viruksen läntisen alatyypin eristettyjä DNA- ja RNA-molekyylejä, näitä sisältäviä vektoreita ja soluviljelmiä sekä menetelmä näiden koodittamien peptidien valmistamiseksi